FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Biogen Idec | Genentech

SPOTLIGHT: Will Rituxan be next MS breakthrough?

Tools


The cancer drug Rituxan cut multiple sclerosis lesions and relapses in a small clinical trial; its developers, Genentech and Biogen Idec, hope to establish its efficacy in larger trials. Report

Bookmark and Share
Get Your FREE FiercePharma Email Newsletter:
Comments (1) | Post a comment
More stories about Biogen Idec   Genentech  

Comments

very interested in the MS trials with Rituxan!

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.